MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 on ClinicalTrials.gov · last registry update 2026-06-25

Closed to new participants; the 151 already enrolled are still being followed. Its estimated completion date, 15 October 2026, has passed with no update to the record. Primary outcome, as filed: Percentage Change in Body Weight from Baseline (Week 9) to Week 20. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Eccogene
Sponsor type: Industry
Enrollment: 151
Started: 2026-03-23
Primary completion: 2026-10-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage Change in Body Weight from Baseline (Week 9) to Week 20

Conditions studied

Adult Obesity · Weight Management

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.